Cells that are about to die send a signal to an executioner protein, but sometimes, those cells can fight back and regenerate ...

When tissue is severely damaged, surviving cells can respond in a concentrated burst of biological repair known as ...

AbbVie and RemeGen are collaborating on RC148, a novel PD-1/VEGF-targeted bispecific antibody already being developed as a ...

US pharma major AbbVie and China’s RemeGen today announced an exclusive licensing agreement for the development, ...

A recent study links chemotherapy to impaired ovarian function and fertility through oxidative damage to ovarian follicles.

A laser. A droplet. Then a 10-micron elephant is born, inside a cell. This isn't science fiction. It's already happening.

AbbVie & RemeGen enter exclusive licensing agreement to develop novel bispecific antibody for advanced solid tumours: North Chicago, Illinois Tuesday, January 13, 2026, 14:00 Hrs ...

Combination therapy of botensilimab (BOT) plus balstilimab (BAL) was approved Monday as an updated national treatment protocol for patients with certain ovarian cancers and soft tissue sarcomas (STS) ...

AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 ...

Chronic inflammation resulting from obesity is considered dangerous and leaves many confused about whether this actually ...

A ₹3.5 crore Madhya Pradesh-funded study on cow dung and urine as cancer treatment raises questions over scientific validity, ...

Even with breakthroughs, treatment for advanced squamous cell carcinoma is more complex. Patients often need more than one treatment. Many patients with this advanced cancer are cared for by a team of ...